Sharda Cropchem Limited's Board of Directors approved the audited consolidated and standalone financial results for the quarter and year ended March 31, 2026. The company reported a robust financial performance for the fiscal year, achieving its highest-ever Return on Capital Employed (RoCE) of 30.4% and Return on Equity (RoE) of 24.2%. Consolidated net profit more than doubled by 124% to ₹681 crores from ₹304 crores in the previous year, while revenue from operations grew by 22% to ₹5,268 crores.

Earnings Call Transcript

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company disclosed the transcript of the earnings call for the Q4 FY 2025-26 Audited Financial Results. The conference call was conducted on Thursday, May 14, 2026, at 01.00 P.M. (IST). Management provided guidance for FY27, expecting revenue growth of 10% to 15% and EBITDA margins to remain in the range of 18% to 20%. Gross margins are anticipated to stay around 35%. The transcript is available on the company's website.

Dividend Declaration

At its Board Meeting held on May 13, 2026, the Board of Directors recommended a final dividend of ₹9.00 per equity share of face value of ₹10.00 each for FY26, subject to shareholder approval at the forthcoming Annual General Meeting. Combined with the interim dividend of ₹6.00 per share paid in December 2025, the total dividend for FY26 aggregates to ₹15.00 per share.

Consolidated Financial Performance

Sharda Cropchem delivered strong growth across key financial metrics. For the full year, EBITDA rose by 69% to ₹1,040 crores, with margins expanding to 19.7% from 14.2% in the previous year. Gross margins improved by 600 basis points to 35.9%. Profit Before Tax (PBT) grew by 126% to ₹855.50 crores, while the PAT margin expanded to 12.9% from 7.0% in FY25. In Q4, consolidated net profit rose 57% year-on-year to ₹318.70 crores from ₹203.60 crores, with Q4 EBITDA growing 75% to ₹512.90 crores and Q4 EBITDA margin expanding to 24.8% from 16.0% year-on-year. The following table summarises the audited consolidated financial results:

Segment and Operational Highlights

The Agrochemicals segment remained the primary growth driver, contributing 90% to total revenue for FY26 with a 25% year-on-year increase to ₹4,717 crores, while the Non-agrochemical segment recorded revenue of ₹551 crores. In Q4 FY26, the Agrochemical segment contributed 93% and the Non-Agrochemical segment contributed 7% to total revenue. Agrochemical volumes grew by 13.3% in FY26, while Non-agrochemical volumes grew by 15.3%, resulting in overall volume growth of 13.4% for the year. The company maintained a debt-free status with cash, bank, and liquid investments of ₹702 crores. Capital expenditure for FY26 stood at ₹505 crores, and product registrations reached 3,011 with 1,004 applications pending globally.

Sharda Cropchem has notified the stock exchanges of its scheduled participation in an institutional investor conference, pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company officials will attend the event on 29 May 2026, representing the company before analysts and institutional investors.

Conference Details

The following table outlines the key details of the scheduled investor conference:

Disclosure and Compliance

The company has clarified that all discussions during the conference will be based on publicly available information. Sharda Cropchem has explicitly stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. The intimation has been submitted in compliance with Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has also noted that changes to the schedule may occur due to exigencies on the part of the host or the company. The disclosure was signed by Jetkin Gudhka, Company Secretary and Compliance Officer of Sharda Cropchem.